Check Before You Invest : Sun Pharma Advanced Research Company Ltd

Snapshot

Q.1 Which industry/sub-sector does Sun Pharma Advanced Research Company Ltd belong to?

Sun Pharma Advanced Research Company Ltd belongs to the Miscellaneous sector, operating specifically within the Business Support segment.

Q.2 Is Sun Pharma Advanced Research Company Ltd a good quality company?

Sun Pharma Advanced Research Company Ltd is a weak quality company, based on a inconsistent 10-year financial track record.

Q.3 Is Sun Pharma Advanced Research Company Ltd undervalued or overvalued?

Sun Pharma Advanced Research Company Ltd appears Overvalued, as its key valuation ratios are above with their past averages.

Q.4 Is Sun Pharma Advanced Research Company Ltd a good buy now?

Sun Pharma Advanced Research Company Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd revenue growth is -5% for FY-2025, which is below its 5-year CAGR of -1.35%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Return on capital employed is -321.18% for FY-2025, which is below its 5-year historical median of -225.57%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Return on Asset is -84.65%, which is below its 5-year historical median of -60.18%, indicating deteriorated asset utilization efficiency.

Q.4 Return on Equity (ROE) of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Return on equity is 0% for FY-2025, which is above its 5-year historical median of -143.72%, indicating the business is making better use of its shareholders capital.

Q.5 Cash conversion cycle of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Cash conversion cycle is -126 days, below its 5-year historical median of -85 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.18	0.43
ROE	-	-143.72
ROCE	-321.18	-225.57
Cash Conversion Cycle	-126 days	-85 days

Q.6 Gross Profit margin of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Gross profit margin which is the profit after deduction of direct costs, is -466% for FY-2025, which is below its 5-year median of -140.8%, indicating decreasing margins.

Q.7 Operating Profit Margin of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -453.56% for FY-2025, which is below its 5-year median of -135.46% indicating decreasing margins.

Q.8 Net Profit Margin of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Net Profit Margin is -481.04% for FY-2025, is below with its 5-year median of -148.19%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-466	-140.8
Operating Profit Margin	-453.56	-135.46
Net Profit Margin	-481.04	-148.19

Q.9 Debt to Equity ratio of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Debt-to-Equity ratio is -1.17, which is lower with the industry average of 0.09, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd Debt to cash flow from operations is -0.71, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Sun Pharma Advanced Research Company Ltd?

Promoters hold 65.67% of the Sun Pharma Advanced Research Company Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Sun Pharma Advanced Research Company Ltd vs industry peers?

Sun Pharma Advanced Research Company Ltd revenue CAGR is -1.35%, compared to the industry median CAGR of 11.02%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-5	11
Gross Profit Growth	0	NAN
Operating Profit Growth	0	14
Net Profit Growth	0	17.7

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.18	0.32
ROE	-	6.73
ROCE	-321.18	12.12
Cash Conversion Cycle (days)	-126.36	50

Valuation & price assessment

Q.1 Stock return of Sun Pharma Advanced Research Company Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -7% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-7%	-3.9%	-9.9%	-1.6%

Q.3 Valuation ratios of Sun Pharma Advanced Research Company Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	-14.57	26.08
Price to Book	-10.8	-13.44	2.53
Price to Sales	87.24	67.64	5.26
EV to EBITDA	-22.94	-30.00	11.21

Check more companies

1. Prime Focus

2. Sagility

3. Syngene Internation.

4. International Gemolo

5. Indegene

6. NESCO

7. Latent View Analytic

8. Smartworks Coworking

9. CMS Info Systems

10. Sun Pharma Adv. Res

Check trending companies

1. Tata Elxsi Ltd.

2. Shree Cement Ltd.

3. Amara Raja Energy & Mobility Ltd.

4. Vishal Mega Mart Ltd.

5. Acme Solar Holdings Ltd.